Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Material and methods br
2024-10-15

Material and methods Results Discussion To develop a novel regenerative and/or neuroprotective therapy for optic neuropathy, including glaucoma, numerous studies have tested new candidates favorable to RGC survival and axon regeneration. Among the many candidate drugs, AdoR modulators are o
-
br Material and methods br Results br Discussion
2024-10-15

Material and methods Results Discussion Clinical gene therapy trials with viral vectors have been in use for treatment of various genetic disorders and diseases, however efficacious, targetable and highly reliable non-viral delivery systems are needed for safe and long-term applications. De
-
Over the past decade extensive research has been directed
2024-10-14

Over the past decade, extensive research has been directed toward the discovery of Aurora-selective small-molecule inhibitors. As a result, a handful of Aurora inhibitors has been identified. Among them, 1 (VX-680) and 2 (SNS-314) have entered human clinical trials as pan-Aurora kinase inhibitors (F
-
Matthew et al synthesized and carried
2024-10-14

Matthew et al. synthesized and carried out SAR studies of imidazo-[1,2-a]-pyrazine as Aurora kinase inhibitors with enhanced kinase selectivity and found that Amodiaquine dihydrochloride dihydrate receptor 39 showed optimal potency on Aurora-A and Aurora-B with IC50 value of 4 nM and 13 nM while on
-
br Conclusions In summary the present results showed that
2024-10-14

Conclusions In summary, the present results showed that ageing diminished arginase activity only in clearance tissues and that l-arginine supplementation did not induce major changes in arginase activity thus refuting a role of arginase in the potential deleterious effects of l-arginine supplemen
-
While increased arginase levels has been shown in animal mod
2024-10-14

While increased arginase levels has been shown in animal models and in humans with cardiovascular dysfunction [16], [22], [23], it is unknown whether plasma levels or activity of Arginase may predict ED risk. In addition, recent evidence suggests that plasma l-arginine hydrolysis by arginases limits
-
Neuropeptide Y 13-36 (porcine) australia Available data thus
2024-10-14

Available data thus indicate that there are at least two ways that HMGA proteins can induce localized changes in the chromatin structure of inducible gene promoters, both of which involve positioned nucleosomes that must be “remodeled” before gene transcription can occur. The first mechanism is exem
-
Testosterone can be converted into estrogens
2024-10-14

Testosterone can be converted into estrogens by aromatase action. Aromatase is encoded by CYP19, belongs to cytochrome P450 superfamily, and synthesizes estradiol (E2) and estrone (E1) from testosterone and androstenedione respectively (Fig. 1). Aromatase is expressed in the ORS of anagen hair folli
-
In view of the ubiquitous distribution of the
2024-10-14

In view of the ubiquitous distribution of the arachidonate 12S-lipoxygenase isoforms and the variety of cellular reactions influenced by the resulting arachidonate metabolites, these products widely play important roles in many biological systems. The development of new type-specific inhibitors of t
-
Decrease in soluble protein content in diabetic lenses
2024-10-14

Decrease in soluble protein content in diabetic lenses compared with those in control lenses in present study could be due to leakage of proteins and insolubilization. T. purpurea treatment could increase the levels of soluble proteins in diabetic lenses may be by preventing cross-linking/aggregatio
-
Various compounds have been designed to inhibit aldose reduc
2024-10-14

Various compounds have been designed to inhibit aldose reductase (AR) [12]. These compounds can be classified into two main categories, the first category comprises those containing a carboxylic jnk inhibitor moiety, for example, 3-thiazolidineacetic acid derivative, which has been reported to be a
-
br Conflict of interest br Acknowledgements
2024-10-12

Conflict of interest Acknowledgements The authors would like to thank Mrs. Amparo Pacheco from CMPL, PUC, for her technical and secretarial assistance. This work was supported by the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1150344, 1050377, 11150083), and the Direccioń
-
Adenosine is a ubiquitous homeostatic substance
2024-10-12

Adenosine is a ubiquitous homeostatic substance released from most cells, including neurons and glias. Endogenous adenosine acts at four principal G-protein-associated receptor subtypes: A1, A2a, A2b and A3 (Ralevic and Burnstock, 1998). The stimulation of adenosine receptors by extracellular adenos
-
Epithelial mesenchymal transition EMT is the process by whic
2024-10-12

Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells are trans-differentiated into motile mesenchymal cells. During EMT, epithelial cells reorganize their cortical HATU cytoskeleton, lose their junctions and apical-basal polarity, change cell shape, and reprogram gene ex
-
br Discussion The clinical course
2024-10-12

Discussion The clinical course of our patient until May 2012 was rather typical of early onset AChR-MG. Later on, the pattern of the disease was more typical of MuSK-MG, as evidenced by the distribution of myasthenic weakness and the unprovoked exacerbations. The Boc-D-Asp(OtBu)-OH.DCHA of MuSK-
16681 records 87/1113 page Previous Next First page 上5页 8687888990 下5页 Last page